previously established a link between elevated MCP-1 levels and the primary clinical manifestations of MM, finding that patients with increased pretreatment MCP-1 concentrations experienced heightened severity of bone disease, renal dysfunction, and anemia (75). Here, CCL2 is linked to anemia.